INS and Sepsis: In terms of antidiabetic medications, insulin use was markedly higher among patients with sepsis (7.3% vs. 2.9%, p < 0.001), while none of the sepsis patients received GLP-1 receptor agonists, compared with 4.1% in the non-sepsis group (p = 0.004) who received them.